Shortcuts to schistosomiasis drug discovery: The state-of-the-art

Abstract The exclusive use of praziquantel for the treatment of schistosomiasis has raised concerns about the urgency of new antischistosomal therapies. Nonetheless, pharmaceutical industry still underinvests in new antischistosomal drugs and current drug discovery approaches present technical limitations. So, the demand for innovative antischistosomal drug discovery approaches gain significance in scientific community. In this scenario, the “automation of drug discovery” bears the promise of making better decisions faster and increasing hit rates in the process. Herein, we focus on the current development in antischistosomal lead discovery, specifically referring to the use of automated whole-organism and target-based screens, fragment-based drug design, and cheminformatics-based decision support. We highlight the strengths and pitfalls of each of the above-mentioned approaches and suggest possible roadmaps toward the integration of several strategies, which may contribute to optimizing research outputs and led to more successful and cost-effective drug discovery endeavors.

[1]  J. Keiser,et al.  Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni , 2015, Parasites & Vectors.

[2]  Jianfeng Pei,et al.  Prediction of Human Cytochrome P450 Inhibition Using a Multitask Deep Autoencoder Neural Network. , 2018, Molecular pharmaceutics.

[3]  Dalia Cohen,et al.  Functional genomics to new drug targets , 2004, Nature Reviews Drug Discovery.

[4]  C. Caffrey Schistosomiasis and its treatment. , 2015, Future medicinal chemistry.

[5]  Y. Baran,et al.  Cell Proliferation and Cytotoxicity Assays. , 2016, Current pharmaceutical biotechnology.

[6]  K. Baumann,et al.  Chemoinformatic Classification Methods and their Applicability Domain , 2016, Molecular informatics.

[7]  Gisbert Schneider,et al.  Automating drug discovery , 2017, Nature Reviews Drug Discovery.

[8]  Mike Preuss,et al.  Planning chemical syntheses with deep neural networks and symbolic AI , 2017, Nature.

[9]  A. Voet,et al.  Fragment based drug design: from experimental to computational approaches. , 2012, Current medicinal chemistry.

[10]  Alexander Tropsha,et al.  Trust, but Verify II: A Practical Guide to Chemogenomics Data Curation , 2016, J. Chem. Inf. Model..

[11]  A. Jadhav,et al.  A 1,536-well-based kinetic HTS assay for inhibitors of Schistosoma mansoni thioredoxin glutathione reductase. , 2008, Assay and drug development technologies.

[12]  M. Sajid,et al.  Schistosomiasis Mansoni: Novel Chemotherapy Using a Cysteine Protease Inhibitor , 2007, PLoS medicine.

[13]  G. Mangiatordi,et al.  Applicability Domain for QSAR models: where theory meets reality , 2016 .

[14]  Anne E Carpenter,et al.  Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening. , 2016, Journal of medicinal chemistry.

[15]  James G. Nourse,et al.  Reoptimization of MDL Keys for Use in Drug Discovery , 2002, J. Chem. Inf. Comput. Sci..

[16]  Diane Joseph-McCarthy,et al.  Fragment-Based Lead Discovery and Design , 2014, J. Chem. Inf. Model..

[17]  M. Sajid,et al.  Blood 'n' guts: an update on schistosome digestive peptidases. , 2004, Trends in parasitology.

[18]  J. McKerrow Update on drug development targeting parasite cysteine proteases , 2018, PLoS neglected tropical diseases.

[19]  Kunal Roy,et al.  How far can virtual screening take us in drug discovery? , 2013, Expert opinion on drug discovery.

[20]  J. Keiser,et al.  The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). , 2014, The Journal of antimicrobial chemotherapy.

[21]  David S. Pires,et al.  Inhibition of histone methyltransferase EZH2 in Schistosoma mansoni in vitro by GSK343 reduces egg laying and decreases the expression of genes implicated in DNA replication and noncoding RNA metabolism , 2018, PLoS neglected tropical diseases.

[22]  James Inglese,et al.  Apparent activity in high-throughput screening: origins of compound-dependent assay interference. , 2010, Current opinion in chemical biology.

[23]  Anne E Carpenter,et al.  QSAR-Driven Discovery of Novel Chemical Scaffolds Active against Schistosoma mansoni , 2016, J. Chem. Inf. Model..

[24]  J. de Moraes,et al.  Anthelmintic Activity of Crude Extract and Essential Oil of Tanacetum vulgare (Asteraceae) against Adult Worms of Schistosoma mansoni , 2014, TheScientificWorldJournal.

[25]  Gianni Chessari,et al.  From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.

[26]  S. Giovanni-De-Simone,et al.  Exploring the subsite specificity of Schistosoma mansoni aspartyl hemoglobinase through comparative molecular modelling , 2002, FEBS letters.

[27]  Sereina Riniker,et al.  Similarity maps - a visualization strategy for molecular fingerprints and machine-learning methods , 2013, Journal of Cheminformatics.

[28]  C. Dissous,et al.  Kinases: Molecular Stage Directors for Schistosome Development and Differentiation. , 2017, Trends in parasitology.

[29]  Thomas Hesterkamp,et al.  Fragments: past, present and future. , 2010, Drug discovery today. Technologies.

[30]  Alexander Tropsha,et al.  Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..

[31]  O. Witt,et al.  HDAC8: a multifaceted target for therapeutic interventions. , 2015, Trends in pharmacological sciences.

[32]  W. Sippl,et al.  Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis. , 2016, Journal of medicinal chemistry.

[33]  Ola Engkvist,et al.  Cheminformatics in Drug Discovery, an Industrial Perspective , 2018, Molecular informatics.

[34]  K. Hoffmann,et al.  Development and Validation of a Quantitative, High-Throughput, Fluorescent-Based Bioassay to Detect Schistosoma Viability , 2010, PLoS neglected tropical diseases.

[35]  Weiwei Liu Epigenetics in Schistosomes: What We Know and What We Need Know , 2016, Front. Cell. Infect. Microbiol..

[36]  Rahul Singh,et al.  Region-Based Segmentation of Parasites for High-throughput Screening , 2011, ISVC.

[37]  Amanda J Price,et al.  Fragment-based drug discovery and its application to challenging drug targets. , 2017, Essays in biochemistry.

[38]  C. Hansch,et al.  p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure , 1964 .

[39]  J. de Moraes,et al.  Antischistosomal agents: state of art and perspectives. , 2018, Future medicinal chemistry.

[40]  D. Chan,et al.  Mass spectrometry for fragment screening. , 2017, Essays in biochemistry.

[41]  J. Keiser,et al.  Development of an in vitro drug screening assay using Schistosoma haematobium schistosomula , 2012, Parasites & Vectors.

[42]  Harren Jhoti,et al.  The 'rule of three' for fragment-based drug discovery: where are we now? , 2013, Nature Reviews Drug Discovery.

[43]  Anthony M Giannetti,et al.  From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance. , 2011, Methods in enzymology.

[44]  F. Mollinedo,et al.  In Vitro and In Vivo Anti-Schistosomal Activity of the Alkylphospholipid Analog Edelfosine , 2014, PloS one.

[45]  Alexander Tropsha,et al.  Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay INterference CompoundS , 2017, J. Chem. Inf. Model..

[46]  S. Altamura,et al.  Development and Validation of a Luminescence-based, Medium-Throughput Assay for Drug Screening in Schistosoma mansoni , 2015, PLoS neglected tropical diseases.

[47]  Anton Simeonov,et al.  Identification of oxadiazoles as new drug leads for the control of schistosomiasis , 2008, Nature Medicine.

[48]  A. Loukas,et al.  Polypyridylruthenium(II) complexes exert anti-schistosome activity and inhibit parasite acetylcholinesterases , 2017, PLoS neglected tropical diseases.

[49]  Andrew L Hopkins,et al.  Fragment screening by surface plasmon resonance. , 2010, ACS medicinal chemistry letters.

[50]  Aine Marie Kelly,et al.  Evidence-based practice: an introduction and overview. , 2009, Seminars in roentgenology.

[51]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[52]  J. M. Gardner,et al.  High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni , 2016, PLoS neglected tropical diseases.

[53]  Vladimir N. Vapnik,et al.  The Nature of Statistical Learning Theory , 2000, Statistics for Engineering and Information Science.

[54]  D. Schollmeyer,et al.  Taste, A New Incentive to Switch to (R)-Praziquantel in Schistosomiasis Treatment , 2009, PLoS neglected tropical diseases.

[55]  Rahul Singh,et al.  Automated image-based phenotypic screening for high-throughput drug discovery , 2009, 2009 22nd IEEE International Symposium on Computer-Based Medical Systems.

[56]  K. C. Oliveira,et al.  Effects of proteasome inhibitor MG-132 on the parasite Schistosoma mansoni , 2017, PloS one.

[57]  H. L. Morgan The Generation of a Unique Machine Description for Chemical Structures-A Technique Developed at Chemical Abstracts Service. , 1965 .

[58]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[59]  C. Dissous,et al.  Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. , 2009, Molecular and biochemical parasitology.

[60]  Wei Huang,et al.  The Schistosoma japonicum genome reveals features of host–parasite interplay , 2009, Nature.

[61]  Russ B Altman,et al.  Machine learning in chemoinformatics and drug discovery. , 2018, Drug discovery today.

[62]  Alex Loukas,et al.  A Novel High Throughput Assay for Anthelmintic Drug Screening and Resistance Diagnosis by Real-Time Monitoring of Parasite Motility , 2010, PLoS neglected tropical diseases.

[63]  L. Goupil,et al.  Introduction: drug discovery and development for neglected diseases. , 2014, Chemical reviews.

[64]  P. Ribeiro,et al.  A Novel G Protein-Coupled Receptor of Schistosoma mansoni (SmGPR-3) Is Activated by Dopamine and Is Widely Expressed in the Nervous System , 2012, PLoS neglected tropical diseases.

[65]  Heather M. Alger,et al.  The disulfide redox system of Schistosoma mansoni and the importance of a multifunctional enzyme, thioredoxin glutathione reductase. , 2002, Molecular and biochemical parasitology.

[66]  K. Hoffmann,et al.  The Diterpenoid 7-Keto-Sempervirol, Derived from Lycium chinense, Displays Anthelmintic Activity against both Schistosoma mansoni and Fasciola hepatica , 2015, PLoS neglected tropical diseases.

[67]  Philippe J Guérin,et al.  The Schistosomiasis Clinical Trials Landscape: A Systematic Review of Antischistosomal Treatment Efficacy Studies and a Case for Sharing Individual Participant-Level Data (IPD) , 2016, PLoS neglected tropical diseases.

[68]  Andrew R. Leach,et al.  An Introduction to Chemoinformatics , 2003 .

[69]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[70]  Jianfeng Pei,et al.  Deep Learning Based Regression and Multiclass Models for Acute Oral Toxicity Prediction with Automatic Chemical Feature Extraction , 2017, J. Chem. Inf. Model..

[71]  Jan Dvorák,et al.  A Multienzyme Network Functions in Intestinal Protein Digestion by a Platyhelminth Parasite* , 2006, Journal of Biological Chemistry.

[72]  C. Andrade,et al.  Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening. , 2019, European journal of medicinal chemistry.

[73]  M. Schlitzer,et al.  Chemotherapy for Fighting Schistosomiasis: Past, Present and Future , 2018, ChemMedChem.

[74]  Brian M. Suzuki,et al.  Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni , 2016, PLoS neglected tropical diseases.

[75]  V. Gladyshev,et al.  Linked Thioredoxin-Glutathione Systems in Platyhelminth Parasites , 2010, The Journal of Biological Chemistry.

[76]  Alexander Tropsha,et al.  Curation of chemogenomics data. , 2015, Nature chemical biology.

[77]  Alán Aspuru-Guzik,et al.  Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules , 2016, ACS central science.

[78]  Ashutosh Kumar Singh,et al.  Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.

[79]  Adriana S. A. Pereira,et al.  Histone deacetylase inhibition modulates histone acetylation at gene promoter regions and affects genome-wide gene transcription in Schistosoma mansoni , 2017, PLoS neglected tropical diseases.

[80]  Ola Engkvist,et al.  Computational prediction of chemical reactions: current status and outlook. , 2018, Drug discovery today.

[81]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[82]  Evan Bolton,et al.  An overview of the PubChem BioAssay resource , 2009, Nucleic Acids Res..

[83]  You-sheng Liang,et al.  Susceptibility or resistance of praziquantel in human schistosomiasis: a review , 2012, Parasitology Research.

[84]  A. Miele,et al.  Fragment-Based Discovery of a Regulatory Site in Thioredoxin Glutathione Reductase Acting as "Doorstop" for NADPH Entry. , 2018, ACS chemical biology.

[85]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[86]  J. Irwin,et al.  An Aggregation Advisor for Ligand Discovery. , 2015, Journal of medicinal chemistry.

[87]  J. Ruiz,et al.  Eukaryotic Protein Kinases (ePKs) of the Helminth Parasite Schistosoma mansoni , 2011, BMC Genomics.

[88]  Jian Wang,et al.  Whole-genome sequence of Schistosoma haematobium , 2012, Nature Genetics.

[89]  Eugene N. Muratov,et al.  QSAR-Based Virtual Screening: Advances and Applications in Drug Discovery , 2018, Front. Pharmacol..

[90]  Björn Krüger,et al.  The holistic integration of virtual screening in drug discovery. , 2013, Drug discovery today.

[91]  Prasenjit Mukherjee,et al.  An overview of molecular fingerprint similarity search in virtual screening , 2016, Expert opinion on drug discovery.

[92]  S. Beckmann,et al.  Imatinib has a fatal impact on morphology, pairing stability and survival of adult Schistosoma mansoni in vitro. , 2010, International journal for parasitology.

[93]  Yuemin Bian,et al.  Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications , 2018, The AAPS Journal.

[94]  Nicholas Furnham,et al.  Computationally-guided drug repurposing enables the discovery of kinase targets and inhibitors as new schistosomicidal agents , 2018, PLoS Comput. Biol..

[95]  A. Leach,et al.  Molecular complexity and fragment-based drug discovery: ten years on. , 2011, Current opinion in chemical biology.

[96]  R. V. van Montfort,et al.  Structure-based drug design: aiming for a perfect fit , 2017, Essays in biochemistry.

[97]  K. Hoffmann,et al.  An Abies procera-derived tetracyclic triterpene containing a steroid-like nucleus core and a lactone side chain attenuates in vitro survival of both Fasciola hepatica and Schistosoma mansoni , 2018, International journal for parasitology. Drugs and drug resistance.

[98]  A. Guidi,et al.  Schistosomiasis control: praziquantel forever? , 2014, Molecular and biochemical parasitology.

[99]  W. Zhan,et al.  Antibodies against Schistosoma japonicum lactate dehydrogenase B enhance enzyme active. , 2018, Molecular and biochemical parasitology (Print).

[100]  Anne E Carpenter,et al.  The antidepressant drug paroxetine as a new lead candidate in schistosome drug discovery , 2016 .

[101]  Rocco Caliandro,et al.  Protein crystallography and fragment-based drug design. , 2013, Future medicinal chemistry.

[102]  Timothy Ravasi,et al.  Defining the protein interaction network of human malaria parasite Plasmodium falciparum. , 2012, Genomics.

[103]  Abhinav Vishnu,et al.  Deep learning for computational chemistry , 2017, J. Comput. Chem..

[104]  D. Fairlie,et al.  Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth , 2016, International journal for parasitology. Drugs and drug resistance.

[105]  S. Rees,et al.  Principles of early drug discovery , 2011, British journal of pharmacology.

[106]  Olexandr Isayev,et al.  Deep reinforcement learning for de novo drug design , 2017, Science Advances.

[107]  Hao Zhu,et al.  Comparing Multiple Machine Learning Algorithms and Metrics for Estrogen Receptor Binding Prediction. , 2018, Molecular pharmaceutics.

[108]  Zhu Chen,et al.  Schistosoma genomics: new perspectives on schistosome biology and host-parasite interaction. , 2009, Annual review of genomics and human genetics.

[109]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[110]  Rahul Singh,et al.  The QDREC web server: determining dose-response characteristics of complex macroparasites in phenotypic drug screens , 2015, Bioinform..

[111]  G. Oliveira,et al.  Epigenetic control of gene function in schistosomes: a source of therapeutic targets? , 2014, Front. Genet..

[112]  Rahul Singh,et al.  Vision-Based Tracking of Complex Macroparasites for High-Content Phenotypic Drug Screening , 2012, ISVC.

[113]  Anton Simeonov,et al.  Quantitative High-Throughput Screen Identifies Inhibitors of the Schistosoma mansoni Redox Cascade , 2008, PLoS neglected tropical diseases.

[114]  J. Comley,et al.  Colorimetric quantitation of filarial viability. , 1989, International journal for parasitology.

[115]  Christos A. Ouzounis,et al.  Rise and Demise of Bioinformatics? Promise and Progress , 2012, PLoS Comput. Biol..

[116]  Q. Bickle,et al.  Comparison of Microscopy and Alamar Blue Reduction in a Larval Based Assay for Schistosome Drug Screening , 2010, PLoS neglected tropical diseases.

[117]  Sean Ekins,et al.  Comparison of Deep Learning With Multiple Machine Learning Methods and Metrics Using Diverse Drug Discovery Data Sets. , 2017, Molecular pharmaceutics.

[118]  F. Brown Chapter 35 – Chemoinformatics: What is it and How does it Impact Drug Discovery. , 1998 .

[119]  Stephen D Pickett,et al.  Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia. , 2016, Journal of medicinal chemistry.

[120]  C. Andrade,et al.  Modern approaches to accelerate discovery of new antischistosomal drugs , 2016, Expert opinion on drug discovery.

[121]  Thomas Blaschke,et al.  The rise of deep learning in drug discovery. , 2018, Drug discovery today.

[122]  Adrià Cereto-Massagué,et al.  Molecular fingerprint similarity search in virtual screening. , 2015, Methods.

[123]  John P. Overington,et al.  The genome of the blood fluke Schistosoma mansoni , 2009, Nature.

[124]  Jiri Gut,et al.  WormAssay: A Novel Computer Application for Whole-Plate Motion-based Screening of Macroscopic Parasites , 2012, PLoS neglected tropical diseases.

[125]  W. Jahnke,et al.  NMR in drug discovery: A practical guide to identification and validation of ligands interacting with biological macromolecules. , 2016, Progress in nuclear magnetic resonance spectroscopy.

[126]  Harren Jhoti,et al.  Twenty years on: the impact of fragments on drug discovery , 2016, Nature Reviews Drug Discovery.

[127]  A. Loukas,et al.  Developmental Sensitivity in Schistosoma mansoni to Puromycin To Establish Drug Selection of Transgenic Schistosomes , 2018, Antimicrobial Agents and Chemotherapy.

[128]  Marwin H. S. Segler,et al.  Neural-Symbolic Machine Learning for Retrosynthesis and Reaction Prediction. , 2017, Chemistry.

[129]  Rahul Singh,et al.  Quantification and clustering of phenotypic screening data using time-series analysis for chemotherapy of schistosomiasis , 2012, BMC Genomics.

[130]  C. Caffrey,et al.  Chemotherapy of schistosomiasis: present and future. , 2007, Current opinion in chemical biology.

[131]  Esben Jannik Bjerrum,et al.  SMILES Enumeration as Data Augmentation for Neural Network Modeling of Molecules , 2017, ArXiv.

[132]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[133]  Marcel Tanner,et al.  Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. , 2006, The Lancet. Infectious diseases.

[134]  Mark Whittaker,et al.  Compound Design by Fragment‐Linking , 2011, Molecular informatics.

[135]  C. Caffrey,et al.  Anthelmintic Drug Discovery: Into the Future , 2015, The Journal of parasitology.

[136]  Isabelle Krimm,et al.  Ligand specificity, privileged substructures and protein druggability from fragment-based screening. , 2011, Current opinion in chemical biology.

[137]  Solomon Nwaka,et al.  Schistosomes: challenges in compound screening , 2007, Expert opinion on drug discovery.

[138]  Sean Ekins The Next Era: Deep Learning in Pharmaceutical Research , 2016, Pharmaceutical Research.

[139]  Regina Barzilay,et al.  Prediction of Organic Reaction Outcomes Using Machine Learning , 2017, ACS central science.

[140]  J. Dearden,et al.  QSAR modeling: where have you been? Where are you going to? , 2014, Journal of medicinal chemistry.

[141]  R. Prichard,et al.  Differential effects of oltipraz and its oxy-analogue on the viability of Schistosoma mansoni and the activity of glutathione S-transferase. , 1991, Biochemical pharmacology.

[142]  Jan Dvorák,et al.  Chapter 4. Peptidases of trematodes. , 2009, Advances in parasitology.

[143]  Scott D. Kahn,et al.  Current Status of Methods for Defining the Applicability Domain of (Quantitative) Structure-Activity Relationships , 2005, Alternatives to laboratory animals : ATLA.

[144]  M. R. Senger,et al.  Filtering promiscuous compounds in early drug discovery: is it a good idea? , 2016, Drug discovery today.

[145]  J. Keiser,et al.  Fluorescence/luminescence-based markers for the assessment of Schistosoma mansoni schistosomula drug assays , 2015, Parasites & Vectors.

[146]  A. Loukas,et al.  Compounds Derived from the Bhutanese Daisy, Ajania nubigena, Demonstrate Dual Anthelmintic Activity against Schistosoma mansoni and Trichuris muris , 2016, PLoS neglected tropical diseases.

[147]  F. Verrey,et al.  The Tegument of the Human Parasitic Worm Schistosoma mansoni as an Excretory Organ: The Surface Aquaporin SmAQP Is a Lactate Transporter , 2010, PloS one.

[148]  C. Unger,et al.  Lactate as a Novel Quantitative Measure of Viability in Schistosoma mansoni Drug Sensitivity Assays , 2014, Antimicrobial Agents and Chemotherapy.

[149]  Alexander Tropsha,et al.  Tuning HERG out: antitarget QSAR models for drug development. , 2014, Current topics in medicinal chemistry.

[150]  M. M. Mourão,et al.  A high-throughput colorimetric assay for detection of Schistosoma mansoni viability based on the tetrazolium salt XTT , 2017, Parasites & Vectors.

[151]  Ian H. Gilbert,et al.  Whole Organism High-Content Screening by Label-Free, Image-Based Bayesian Classification for Parasitic Diseases , 2012, PLoS neglected tropical diseases.

[152]  Hélène Decornez,et al.  Early phase drug discovery: cheminformatics and computational techniques in identifying lead series. , 2012, Bioorganic & medicinal chemistry.

[153]  Daniel A Erlanson,et al.  Learning from our mistakes: the 'unknown knowns' in fragment screening. , 2013, Bioorganic & medicinal chemistry letters.

[154]  I. Kuntz,et al.  The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[155]  P. Brindley,et al.  Gene function in schistosomes: recent advances toward a cure , 2015, Front. Genet..

[156]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[157]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[158]  N. Foloppe The benefits of constructing leads from fragment hits. , 2011, Future medicinal chemistry.

[159]  Roderick E. Hubbard,et al.  Current perspectives in fragment-based lead discovery (FBLD) , 2017, Essays in biochemistry.

[160]  Liliana Rojo-Arreola,et al.  Chemical and Genetic Validation of the Statin Drug Target to Treat the Helminth Disease, Schistosomiasis , 2014, PloS one.

[161]  R. Abagyan,et al.  Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target , 2017, PLoS neglected tropical diseases.

[162]  C. Cass,et al.  Investigations of the catalytic mechanism of thioredoxin glutathione reductase from Schistosoma mansoni. , 2011, Biochemistry.

[163]  Jianying Hu,et al.  Predicting adverse drug reactions through interpretable deep learning framework , 2018, BMC Bioinformatics.

[164]  Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma mansoni , 2018, Parasites & Vectors.

[165]  D. Scott,et al.  Fragment-based approaches in drug discovery and chemical biology. , 2012, Biochemistry.

[166]  Esben Jannik Bjerrum,et al.  Improving Chemical Autoencoder Latent Space and Molecular De Novo Generation Diversity with Heteroencoders , 2018, Biomolecules.

[167]  Roderick E Hubbard,et al.  Experiences in fragment-based lead discovery. , 2011, Methods in enzymology.

[168]  E. Kellenberger,et al.  Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme. , 2010, Bioorganic & medicinal chemistry.

[169]  A. Brancale,et al.  Combining bioinformatics, cheminformatics, functional genomics and whole organism approaches for identifying epigenetic drug targets in Schistosoma mansoni , 2018, International journal for parasitology. Drugs and drug resistance.

[170]  Conor R. Caffrey,et al.  Drug Discovery for Schistosomiasis: Hit and Lead Compounds Identified in a Library of Known Drugs by Medium-Throughput Phenotypic Screening , 2009, PLoS neglected tropical diseases.

[171]  G. M. Ferreira,et al.  Fragment‐based drug discovery as alternative strategy to the drug development for neglected diseases , 2017, Chemical biology & drug design.

[172]  David S. Millan,et al.  Fragment based discovery of a novel and selective PI3 kinase inhibitor. , 2011, Bioorganic & medicinal chemistry letters.

[173]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[174]  A. Loukas,et al.  Identification of lead chemotherapeutic agents from medicinal plants against blood flukes and whipworms , 2016, Scientific Reports.

[175]  E. Davioud‐Charvet,et al.  Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug Target , 2007, PLoS medicine.

[176]  Robert P. Sheridan,et al.  Random Forest: A Classification and Regression Tool for Compound Classification and QSAR Modeling , 2003, J. Chem. Inf. Comput. Sci..

[177]  S. Harper,et al.  Discovery by organism based high-throughput screening of new multi-stage compounds affecting Schistosoma mansoni viability, egg formation and production , 2017, PLoS neglected tropical diseases.

[178]  J. DiMasi,et al.  Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs , 2010, Clinical pharmacology and therapeutics.

[179]  J. Keiser,et al.  Isothermal Microcalorimetry To Study Drugs against Schistosoma mansoni , 2011, Journal of Clinical Microbiology.

[180]  S. H. Silva,et al.  In vitro schistosomicidal activity of curcumin against Schistosoma mansoni adult worms , 2009, Parasitology Research.

[181]  Evan Bolton,et al.  PubChem's BioAssay Database , 2011, Nucleic Acids Res..

[182]  Adhemar Zerlotini,et al.  A Systematically Improved High Quality Genome and Transcriptome of the Human Blood Fluke Schistosoma mansoni , 2012, PLoS neglected tropical diseases.

[183]  L. Stewart,et al.  Predicting the success of fragment screening by X-ray crystallography. , 2011, Methods in enzymology.

[184]  Rahul Singh,et al.  Segmenting the Etiological Agent of Schistosomiasis for High-Content Screening , 2013, IEEE Transactions on Medical Imaging.

[185]  György G Ferenczy,et al.  How are fragments optimized? A retrospective analysis of 145 fragment optimizations. , 2013, Journal of medicinal chemistry.

[186]  N M Luscombe,et al.  What is Bioinformatics? A Proposed Definition and Overview of the Field , 2001, Methods of Information in Medicine.

[187]  Brian M. Suzuki,et al.  Sertraline, Paroxetine, and Chlorpromazine Are Rapidly Acting Anthelmintic Drugs Capable of Clinical Repurposing , 2018, Scientific Reports.

[188]  J. Irelan,et al.  Viability of developmental stages of Schistosoma mansoni quantified with xCELLigence worm real-time motility assay (xWORM) , 2015, International journal for parasitology. Drugs and drug resistance.

[189]  Stephen W. Fesik,et al.  Fragment-based drug discovery using NMR spectroscopy , 2013, Journal of biomolecular NMR.

[190]  A. Westwell,et al.  Design, synthesis and anthelmintic activity of 7-keto-sempervirol analogues. , 2018, European journal of medicinal chemistry.

[191]  R. Gasser,et al.  Working towards New Drugs against Parasitic Worms in a Public-Development Partnership. , 2018, Trends in parasitology.

[192]  E. Perlas,et al.  Discovery and Characterization of Novel Anti-schistosomal Properties of the Anti-anginal Drug, Perhexiline and Its Impact on Schistosoma mansoni Male and Female Reproductive Systems , 2016, PLoS neglected tropical diseases.

[193]  P. Ribeiro,et al.  Serotonin Signaling in Schistosoma mansoni: A Serotonin–Activated G Protein-Coupled Receptor Controls Parasite Movement , 2014, PLoS pathogens.

[194]  Roderick E Hubbard,et al.  How well can fragments explore accessed chemical space? A case study from heat shock protein 90. , 2011, Journal of medicinal chemistry.

[195]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[196]  Connor W. Coley,et al.  Machine Learning in Computer-Aided Synthesis Planning. , 2018, Accounts of chemical research.

[197]  Jean-Louis Reymond,et al.  Virtual Exploration of the Chemical Universe up to 11 Atoms of C, N, O, F: Assembly of 26.4 Million Structures (110.9 Million Stereoisomers) and Analysis for New Ring Systems, Stereochemistry, Physicochemical Properties, Compound Classes, and Drug Discovery , 2007, J. Chem. Inf. Model..

[198]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[199]  Monya Baker,et al.  Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.

[200]  P. Brindley,et al.  Drug Repurposing for Schistosomiasis: Combinations of Drugs or Biomolecules , 2018, Pharmaceuticals.